video

sound

Persian Version

View:

45,182

Download:

20,665

Cites:

Information Journal Paper

Title

ITRACONAZOLE NANOSUSPENSION FOR ORAL DELIVERY: FORMULATION, CHARACTERIZATION AND IN VITRO COMPARISON WITH MARKETED FORMULATION

Pages

  84-90

Abstract

 Background and the purpose of the study: ITRACONAZOLE is a poorly water soluble drug which results in its insufficient bioavailability. The purpose of the present study was to formulate ITRACONAZOLE in a NANOSUSPENSION to increase the aqueous solubility and to improve its formulation related parameters, dissolution and hence oral bioavailability.Methods: ITRACONAZOLE NANOSUSPENSION was prepared by PEARL MILLING TECHNIQUE using zirconium oxide beads as a milling media, Poloxamer 407 as a stabilizer and glycerol as a wetting agent. Effects of various process parameters like, stirring time and the ratio of the beads were optimized by keeping drug:surfactant: milling media (1:3.0:50) as a constant initially and then optimized process parameters were used to optimize formulation parameters by 32 factorial designs. The optimized NANOSUSPENSION was lyophilized using mannitol (1:1 ratio) as a cryoprotectant. NANOSUSPENSION was characterized by particle size and size distribution, drug content, scanning electron microscopy, differential scanning colorimetry and X-ray diffraction techniques.Results: Optimized NANOSUSPENSION showed spherical shape with surface oriented surfactant molecules and a mean particle diameter of 294 nm. There was no significant change in crystalline nature after formulation and it was found to be chemically stable with high drug content.Conclusion: The in vitro dissolution profile of the optimized formulation compared to the pure drug and marketed formulation (Canditral Capsule) by using 0.1N Hydrochloric acid as release medium showed higher drug release.

Cites

  • No record.

    • References

  • No record.

    • Cite

    APA: Copy

    NAKARANI, M., MISRA, A.K., PATEL, J.K., & VAGHANI, S.S.. (2010). ITRACONAZOLE NANOSUSPENSION FOR ORAL DELIVERY: FORMULATION, CHARACTERIZATION AND IN VITRO COMPARISON WITH MARKETED FORMULATION. DARU JOURNAL OF PHARMACEUTICAL SCIENCE, 18(2), 84-90. SID. https://sid.ir/paper/275565/en

    Vancouver: Copy

    NAKARANI M., MISRA A.K., PATEL J.K., VAGHANI S.S.. ITRACONAZOLE NANOSUSPENSION FOR ORAL DELIVERY: FORMULATION, CHARACTERIZATION AND IN VITRO COMPARISON WITH MARKETED FORMULATION. DARU JOURNAL OF PHARMACEUTICAL SCIENCE[Internet]. 2010;18(2):84-90. Available from: https://sid.ir/paper/275565/en

    IEEE: Copy

    M. NAKARANI, A.K. MISRA, J.K. PATEL, and S.S. VAGHANI, “ITRACONAZOLE NANOSUSPENSION FOR ORAL DELIVERY: FORMULATION, CHARACTERIZATION AND IN VITRO COMPARISON WITH MARKETED FORMULATION,” DARU JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 18, no. 2, pp. 84–90, 2010, [Online]. Available: https://sid.ir/paper/275565/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops